AbCellera Biologics Inc. (ABCL) /
The debt of AbCellera Biologics Inc. over the past 7 years
Chart AbCellera Biologics Inc.: liquid cash, total debt, net cash, fiscal 2019–2025 Open the chart →At the end of fiscal 2025, the latest fiscal year on file, AbCellera Biologics Inc. had liquid cash of $533.83M and total debt of $0: net cash of $533.83M. It had more liquid cash than debt at all 6 year-ends shown.
Year by year
| Fiscal year | Liquid cash | Total debt* | Net cash* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $533.83M | $0 | $533.83M |
| 2024ended Dec 31, 2024 | $625.61M | $0 | $625.61M |
| 2023ended Dec 31, 2023 | $760.59M | $0 | $760.59M |
| 2022ended Dec 31, 2022 | $886.49M | $0 | $886.49M |
| 2021ended Dec 31, 2021 | $722.98M | $0 | $722.98M |
| 2020ended Dec 31, 2020 | $594.12M | $0 | $594.12M |
| 2019ended Dec 31, 2019 | — | — | — |
Fiscal years as AbCellera Biologics Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on AbCellera Biologics Inc.
- The revenue of AbCellera Biologics Inc.
- The profitability of AbCellera Biologics Inc.
- The cash flow of AbCellera Biologics Inc.
- All of AbCellera Biologics Inc.'s financials, charted
Companies of a similar size
- GEOThe GEO Group, Inc.
- RUSHARUSH ENTERPRISES, INC.
- EQPTEquipmentShare.com Inc
- SLMSLM Corp
- ACMRACM Research, Inc.
Not investment advice. This page shows what AbCellera Biologics Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.